Theoretically, we may agree with the higher inhibition effects of Ibrutinib in HER2, HER4, TEC (mainly related to AF) (62) and fewer off-target effects of Zanubrutinib with lower IC50 against BTK (mainly related to the treatment of lymphoma) and higher IC50 for other kinases like EGFR(21nM), TEC(44nM), ITK(50nM) (63). The gene discussed is ERBB2; the disease is lymphoma.